Protein / target
Sodium channel protein type 1 subunit alpha
Protein at a glance
Biological role
Voltage-gated sodium channel activity
Primary system
Nervous system
Strongest disease association
generalized epilepsy with febrile seizures plus, type 2
Therapeutic maturity
Clinically validated target
Druggability
Small molecule
Clinical development
59 approved · 9 in clinical development
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function
Pore-forming subunit of Nav1.1, a voltage-gated sodium (Nav) channel that directly mediates the depolarizing phase of action potentials in excitable membranes. Navs, also called VGSCs (voltage-gated sodium channels) or VDSCs (voltage-dependent sodium channels), operate by switching between closed and open conformations depending on the voltage difference across the membrane. In the open conformation they allow Na(+) ions to selectively pass through the pore, along their electrochemical gradient. The influx of Na(+) ions provokes membrane depolarization, initiating the propagation of electrical signals throughout cells and tissues (PubMed:14672992). By regulating the excitability of neurons, ensures that they respond appropriately to synaptic inputs, maintaining the balance between excitation and inhibition in brain neural circuits (By similarity). Nav1.1 plays a role in controlling the excitability and action potential propagation from somatosensory neurons, thereby contributing to the sensory perception of mechanically-induced pain (By similarity)
Subcellular location
Domains and Gene Ontology detail (16)Hide
Domains & features
Gene Ontology
- Caxon initial segment
- Cintercalated disc
- Cneuronal cell body
- Cnode of Ranvier
- Cplasma membrane
- CT-tubule
- Cvoltage-gated sodium channel complex
- CZ disc
- Fvoltage-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potential
- Fvoltage-gated sodium channel activity
- Pcardiac muscle cell action potential involved in contraction
- Pdetection of mechanical stimulus involved in sensory perception of pain
Biological roles
What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.
View supporting evidenceHide supporting evidence
Ion channel gating
- ·voltage-gated monoatomic ion channel activity involved in regulation of presynaptic memb…
- ·sodium ion transmembrane transport
Synaptic signalling
- ·voltage-gated monoatomic ion channel activity involved in regulation of presynaptic memb…
Immune signalling
- ·Pore-forming subunit of Nav1.1, a voltage-gated sodium (Nav) channel that directly media…
View underlying pathways (2)Hide underlying pathways
Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.
Interaction neighbourhood
Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.
Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.
Drugs targeting this protein
Whether each drug engages this protein directly or through a complex, and how many other targets are recorded for it. Direct binders with few recorded targets are listed first.
Sodium channel alpha subunit blocker
Appears in clinical studies involving amyotrophic lateral sclerosis, progressive supranuclear palsy, multiple system atrophy, Huntington disease
Sodium channel alpha subunit blocker
Appears in clinical studies involving epilepsy, bipolar disorder, major depressive disorder, Seizure
ChEMBL mechanism, action type and target identity. Open Targets clinical status and indications.
Translational evidence
Why this target matters therapeutically — disease associations, drugs in development, tractability and safety, from Open Targets.
Strongest genetic associations
Human genetic evidence — the most direct causal link between this target and a disease.
Highest-confidence therapeutic associations
Diseases where a drug acting on this target has already reached clinical development.
Highest overall evidence
Remaining associations by Open Targets' aggregated evidence score.
Show all associationsHide all associations
Open Targets ranks 1,918 associations for this target and we store the top 10 by aggregated score. The long tail is largely literature co-mention and RNA-expression evidence, not evidence that this target drives those diseases.
Known drugs · 72 total
atrial fibrillation
Parkinson disease
Ventricular arrhythmia · malaria
premature ejaculation · Pruritus · burn
Ventricular arrhythmia · cardiac arrhythmia
Seizure · epilepsy · Seizure
cardiac arrhythmia · Arrhythmia · atrial fibrillation
Pain · diabetes mellitus
epilepsy · migraine disorder · Lennox-Gastaut syndrome
Tractability
Safety liabilities
Clinical trials
Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein.
Show remaining trials (24)Hide
ClinicalTrials.gov via the drug-target graph.
Forefront confidence
Our own weighting of the evidence behind each disease association. Human genetics and clinical evidence count for most; literature co-mention counts for little, because two entities sharing an abstract is not evidence that one drives the other.
The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the underlying per-type scores are shown above so the calculation can be checked.
What's happening now
Recent activity around this target, drawn from one canonical event stream. Every item is reached through 2 drugs that target this protein, so each event is news about that drug rather than about the protein directly.
- Label change
Label change: LAMOTRIGINE (ANDA206382)
- Label change
Label change: LAMOTRIGINE (NDA218879)
- Label change
Label change: LAMOTRIGINE (NDA218879)
- Label change
Label change: LAMOTRIGINE (ANDA219677)
- Label change
Label change: LAMOTRIGINE (ANDA204158)
- Label change
Label change: LAMOTRIGINE (ANDA204158)
- Label change
Label change: LAMOTRIGINE (ANDA204158)
- Label change
Label change: LAMOTRIGINE (ANDA204158)
- Label change
Label change: LAMOTRIGINE (ANDA090401)
- Label change
Label change: LAMOTRIGINE (NDA022251)
- Label change
Label change: LAMOTRIGINE (NDA022251)
- Regulatory approval
Approval: LAMOTRIGINE (ANDA219677)
Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.